| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02736578 Details | 2019-06-25 Interventional | 2 | [1 Refs] | 8 | Cetuximab Pancreatic Aden… | Logistics - | ||
| NCT00748189 Details | 2019-06-25 Interventional | 3 | 447 | Chlorambucil Ofatumumab Leukemia Leukemia, Lymph… Leukemia, Lymph… Leukaemia, Lymp… | Majority of patients (62%) had been treated with next line therapies, including new highly
effective therapies confounding the interpretation of the OS results. - | |||
| NCT00448864 Details | 2019-06-25 Interventional | 2 | 75 | Ecallantide Blood Loss, Sur… Hemorrhage | Experience gained from this study is sufficient to design and facilitate the follow-on study. - | |||
| NCT02762331 Details | 2019-06-24 Interventional | 1 | 6 | Ascorbic Acid Atrial Fibrilla… Heart Valve Dis… Complications D… Disorder of Vit… Heart Valve Dis… | Therapy shown effective by larger studies - | |||
| NCT01987375 Details | 2019-06-24 Interventional | 1 | 1 | Cetuximab Head and Neck N… Head and Neck C… | logistics - | |||
| NCT03642145 Details | 2019-06-21 Interventional | 3 | 0 | Deflazacort Muscular Dystro… Muscular Dystro… Duchenne Muscul… | Study is no longer necessary given the safety and efficacy of emflaza in this age range has
already been established after review of already available data. - | |||
| NCT02494102 Details | 2019-06-20 Interventional | 4 | 105 | Modafinil Apnea Delayed Emergen… Sleep Apnea Syn… Sleep Apnea, Ob… Delayed Emergen… Obstructive Sle… | - Trial terminated for statistical futility on scheduled interim analysis | |||
| NCT02524106 Details | 2019-06-19 Interventional | 3 | 11 | Bococizumab Cardiovascular … Dyslipidemias Cardiovascular … Dyslipidemia | Industry won't be moving forward with production of bococizumab - | |||
| NCT01247922 2010-023478-38 Details | 2019-06-19 Interventional | 2 | 4 | Erlotinib Hydro… Ependymoma | In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety
concerns. As a result, the companion trial, OSI-774-206 has been stopped Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages. | |||
| NCT01176318 Details | 2019-06-19 Interventional | 4 | 0 | Erdosteine Lung Diseases Lung Diseases, … Pulmonary Disea… Chronic Obstruc… | grant was withdrawn no financial support to conduct the study. - | |||
| NCT01032070 2009-016836-11 Details | 2019-06-19 Interventional | 2 | 25 | Erlotinib Hydro… Etoposide Ependymoma Recurrence Recurrent or Re… | In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety
concerns. As a result, it has been stopped. Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages. | |||
| NCT02160041 Details | 2019-06-18 Interventional | 2 | 84 | Infigratinib Hematologic Neo… Neoplasms Hematologic Mal… Solid Tumor | - - | |||
| NCT01853228 2013-000390-70 Details | 2019-06-17 Interventional | 1/2 | 17 | Cytarabine Decitabine Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | EMA/PDCO acknowledged that available results from this study do not support further clinical
studies in relapsed/refractory AML paediatric patients. The Sponsor terminated the study earlier than planned due to lack of efficacy with 8 evaluable participants in Phase 2 with no clinically meaningful anti-leukemic activity. | |||
| NCT02918266 Details | 2019-06-14 Interventional | 1 | 18 | Butylscopolammo… Donepezil Scopolamine Cognitive Dysfu… Healthy Volunte… | Terminated prematurely due to indication change. - | |||
| NCT02744833 Details | 2019-06-14 Interventional | 1/2 | 2 | Enoxaparin Enoxaparin sodi… Thrombosis Venous Thrombos… Deep Venous Thr… | The trial was funded in part by a grant; the trial closed when the grant ended. - | |||
| NCT02431260 Details | 2019-06-14 Interventional | 1/2 | 69 | INCB054329 Hematologic Neo… Neoplasms Solid Tumors an… | As of 31 JAN 2018, the study was terminated by the sponsor due to PK variability. - | |||
| NCT03348904 Details | 2019-06-13 Interventional | 3 | 2 | Carboplatin Gemcitabine Nivolumab Paclitaxel Pemetrexed Carcinoma, Non-… Lung Neoplasms Lung Cancer | Study halted prematurely and will not resume; participants are no longer being examined or
receiving intervention. - | |||
| NCT02608931 Details | 2019-06-13 Interventional | 2 | 0 | Dronabinol Autonomic Nervo… Dysautonomia, F… Nausea Primary Dysauto… Vomiting Familial Dysaut… | Unable to begin study with drug provider - | |||
| NCT02206932 Details | 2019-06-13 Interventional | 4 | 0 | Simeprevir Sofosbuvir Hepatitis Hepatitis A Hepatitis C Hepatitis C, Ch… HIV CDC Categor… | never opened - | |||
| NCT03715023 2018-001667-24 Details | 2019-06-12 Interventional | 2 | 5 | PC-786 Communicable Di… Infections Respiratory Syn… | Practical issues that could not be resolved resulting in recruitment difficulties at sites. - |